Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

 
Each year over 200,000 men are newly diagnosed with PCa in the US alone.  CPC-100 was designed for men (e.g. 170,000 US men who fail prostate removal & ADP)  with no available approved drug. 

Dir. Alex Zhavoronkov, PhD

Director of Business Development

 

Alex Zhavoronkov, PhD has over ten years of experience in business development, marketing and general management in information technology and life sciences industries. Prior to joining Colby Pharmaceutical Company, Dr. Zhavoronkov had a successful career as Sales Director at ATI Technologies, Inc, President of Mediox, Inc. and Director of Business Development at GTCbio.
He is also a trustee and head of fundraising at Biogerontology Research Foundation, a UK-based charity organization focused on alleviating suffering in the elderly.

Dr. Zhavoronkov holds a Bachelor of Commerce and Bachelor of Science degrees from Queen’s University, a Master of Science degree from John Hopkins University and a PhD degree from Moscow State University.